At the forefront of therapies for rare and orphan diseases
TM
HOME
CONTACT US
Share
about us
|
programs
|
science & technology
|
patient advocacy
|
clinical studies
|
investors
|
collaborations
|
news & events
overview
welcome from chairman & CEO
leadership
amicus belief statement
careers
contact us
development pipeline
fabry disease
pompe disease
preclinical programs
overview
protein misfolding & disease
pharmacological chaperone technology
chaperone-ERT combinations
posters, abstracts & publications
patient advocacy at amicus
general disease information
patient portraits
patient advisory boards
resources
community support
ongoing clinical studies
investors
senior management team
board of directors
corporate governance
press releases
events and presentations
SEC filings
stock performance
investor FAQs
contact us
events
press releases
media
Amicus Therapeutics
is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
06/17/2013
Amicus Therapeutics to Host Conference Call Today at 8:00 a.m. ET to Discuss Regulatory Strategy for Migalastat HCl Monotherapy for Fabry Disease
05/30/2013
Amicus Therapeutics to Present at Jefferies 2013 Global Healthcare Conference
05/14/2013
Amicus Therapeutics to Present at UBS Global Healthcare Conference
More...
About Pharmacological Chaperones
About CHART™
Copyright © 2013 Amicus Therapeutics, Inc. All rights reserved.
Terms of Use
|
Privacy Policy
